Bicycle Therapeutics (BCYC) Assets Average (2019 - 2026)

Bicycle Therapeutics has reported Assets Average for 8 years, with the latest figure at $685.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 25.57% year-over-year to $685.0 million; the trailing twelve-month figure through Mar 2026 stood at $685.0 million (down 25.57% YoY), and the FY2025 full-year result was $837.2 million, up 7.88% from the prior year.
• Assets Average for Q1 2026 stood at $685.0 million, down from $740.8 million in the prior quarter.
• The five-year high for Assets Average was $1.0 billion in Q3 2024, with the low at $413.9 million in Q4 2022.
• Historically, Assets Average has averaged $657.2 million across 5 years, with a median of $617.0 million in 2023.
• Annual changes were most pronounced in 2022 — Assets Average jumped 143.99% — and 2026, when it fell 25.57%.
• Bicycle Therapeutics' Assets Average stood at $413.9 million in 2022, then jumped by 49.08% to $617.0 million in 2023, then jumped by 58.31% to $976.8 million in 2024, then retreated by 24.16% to $740.8 million in 2025, then declined by 7.53% to $685.0 million in 2026.
• The last three Assets Average figures came in at $685.0 million (Q1 2026), $740.8 million (Q4 2025), and $798.1 million (Q3 2025), per Business Quant data.